Latest Biotech News

Eikon Therapeutics priced an upsized IPO at $381 million, the largest biotech float since 2024, and said proceeds will prioritize development of EIK‑1001 and other oncology candidates. The...

Generate:Biomedicines, the Flagship Pioneering‑backed AI drug company, filed to go public while highlighting GB‑0895 and other antibody programs as IPO priorities. The filing arrives as the sector...

Veradermics priced an upsized $256.3 million IPO to fund pivotal trials of its oral minoxidil formulation (VDPHL‑01) targeting pattern hair loss. Management said the cash will support three...

The FDA issued a safety communication clarifying that the DPYD (dihydropyrimidine dehydrogenase) deficiency labeling update applies to both capecitabine (Xeloda) and intravenous 5‑fluorouracil...

BARDA opened the first phase of a $100 million prize competition aimed at advancing broad‑spectrum small‑molecule antivirals against Togaviridae and Flaviviridae families. The agency will award...

The Biotechnology Innovation Organization (BIO) praised Congress’s reauthorization of the Pediatric Priority Review Voucher (PPRV) through 2029 and inclusion of PBM reform measures in the recent...

Eikon Therapeutics priced an upsized initial public offering that raised roughly $381 million to fund clinical development of its oncology-focused programs. The company, built around...

Hims & Hers began offering a compounded pill version of Novo Nordisk’s Wegovy shortly after the FDA approved the branded oral formulation, prompting immediate industry and regulatory scrutiny. The...

Eli Lilly reported financial results and guidance that outperformed expectations, driven by robust sales of tirzepatide products (Mounjaro/Zepbound), and sent its stock sharply higher. Lilly...

Bayer disclosed Phase 3 results showing its factor XIa inhibitor asundexian reduced recurrent ischemic stroke by 26% versus comparator in a secondary‑prevention population, with no major safety...

Roivant spinout Priovant reported Phase 2 data showing brepocitinib—a TYK2/JAK1 inhibitor inherited from Pfizer—significantly outperformed placebo in cutaneous sarcoidosis, registering...

The U.S. Biomedical Advanced Research and Development Authority (BARDA) launched the first stage of a $100 million prize competition aimed at stimulating development of broad‑spectrum,...

Insilico Medicine announced the selection of ISM5059, a peripheral‑restricted NLRP3 inhibitor discovered using generative AI platforms, as its lead preclinical candidate. The company reported that...

Generate:Biomedicines, a Flagship Pioneering‑backed biotech that applies machine learning to antibody and protein engineering, filed to go public while advancing an anti‑TSLP antibody into Phase 3...

Researchers unveiled NEO‑STIM, a platform that refines neoantigen‑specific adoptive T‑cell therapy by improving selection and stimulation of patient‑specific tumor antigens. The...

More than two years after FDA approval, Vertex’s CRISPR‑based sickle‑cell therapy Casgevy has treated only about 60 patients globally, with centers reporting difficulty collecting sufficient cells...

Belgian immunology developer Agomab Therapeutics and ocular drug delivery company SpyGlass Pharma priced listings on Nasdaq, collectively raising about $350 million. Agomab secured roughly $200...

Eikon Therapeutics completed an upsized Nasdaq offering that raised $381 million, marking the largest biotech IPO since 2024. The San Francisco oncology company plans to direct proceeds toward...

Veradermics raised $256 million in an IPO to fund three pivotal trials of its oral minoxidil candidate for pattern hair loss. The New Haven-based company positioned the offering to advance phase...

Generate:Biomedicines, the Flagship-backed platform that uses AI to design protein therapeutics, filed for an IPO as it advances phase 3 and earlier-stage antibody and CAR-T programs. The filing...